Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience.

Mar RondaSandra Pérez-RecioMònica González LagunaMaria de la Fe Tubau QuintanoJosep Llop TalaveronLaura Soldevila-BoixaderJordi CarratalàGuillermo CuervoAriadna Padullés

Published in: Journal of clinical pharmacy and therapeutics (2022)

C/T showed a favourable clinical profile for difficult-to-treat multidrug-resistant and carbapenem-resistant Gram-negative infections, regardless of the source of infection.

Keyphrases

gram negative
multidrug resistant
drug resistant
acinetobacter baumannii
klebsiella pneumoniae
escherichia coli
pseudomonas aeruginosa
cystic fibrosis